ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial ...
Revenue growth in 2025 was tempered by lower entitlement growth and a moderation in upsell/cross-sell activity compared to ...
Vertex, Inc. (NASDAQ: VERX) ("Vertex" or the "Company"), a leading global provider of indirect tax solutions, today announced financial results ...
Vertex, Inc. (NASDAQ: VERX) ('Vertex” or the 'Company”), a leading global provider of indirect tax solutions, today announced ...
Vertex Pharmaceuticals (NasdaqGS:VRTX) entered an agreement with WuXi Biologics to co-develop a trispecific T-cell Engager ...
Jupiter Endovascular, Inc. announced completion of patient enrollment in the SPIRARE II pivotal clinical trial evaluating the c ...
Google Cloud partner 66degrees explains Gemini Enterprise customer wins, data and AI services growth, Google innovation and ...
Rep. Jake Auchincloss of Massachusetts said the Commissioner’s National Priority Voucher program did not receive congressional backing. The FDA has also not yet made disclosures for eight senior ...
Jupiter Endovascular completes enrollment in a pivotal trial of its Vertex system with Transforming Fixation technology for ...
China-based biologics CDMO WuXi Biologics (HKEX: 2269) has signed a license and research services agreement with US biotech Vertex Pharmaceuticals (Nasdaq: VRTX) covering a preclinical trispecific ...
Earlier, on January 23, Evercore ISI lifted the price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $530 ...
Under the agreement, participating states will receive “discounts and rebates” from the drugmakers if the treatments don’t work as promised, according to the Centers for Medicare & Medicaid Services.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results